1. Home
  2. WGRX vs NEUP Comparison

WGRX vs NEUP Comparison

Compare WGRX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wellgistics Health Inc.

WGRX

Wellgistics Health Inc.

HOLD

Current Price

$0.24

Market Cap

25.6M

Sector

Health Care

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.34

Market Cap

23.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WGRX
NEUP
Founded
2022
1996
Country
United States
United States
Employees
N/A
8
Industry
Other Pharmaceuticals
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.6M
23.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WGRX
NEUP
Price
$0.24
$4.34
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
783.9K
22.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$3.65
52 Week High
$7.04
$21.31

Technical Indicators

Market Signals
Indicator
WGRX
NEUP
Relative Strength Index (RSI) 29.20 61.86
Support Level N/A $3.99
Resistance Level $0.45 $4.43
Average True Range (ATR) 0.03 0.15
MACD -0.00 0.04
Stochastic Oscillator 18.04 82.16

Price Performance

Historical Comparison
WGRX
NEUP

About WGRX Wellgistics Health Inc.

Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: